Advertisement

NMR as an Aid in Studying N-Alkylformamides and Metabolites

  • Michael D. Threadgill
  • Andreas Gescher
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 18 A)

Abstract

The common industrial and laboratory solvent DMF≠ and its close analogue NMF share the ability to cause hepatotoxicity in man. They differ, however, in their biological properties towards rodents. NMF is a hepatotoxin towards rats and mice and shows significant activity against tumours of murine [1] and human [2] origin grown in mice. DMF shows neither strong therapeutic nor hepatotoxic activity in mice, whereas NEF in mice shows hepatoxicity only [1, 3]. The explanation for these comparisons and contrasts may be connected with the nature and quantity of the metabolites formed from different N-alkylformamides in the various species. The characterization of the urinary metabolites by conventional techniques such as MS and UV spectrometry is hampered by their lability and lack of a suitable chromophore.

Keywords

Urinary Metabolite Free Induction Decay Mercapturic Acid Developmental Therapeutics Program Cancer Research Campaign 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviation

N,N-dimethyl

DMF

N-methyl

NMF

N-ethyl

NEF; see over for HMMF

N-acetyl-S-(N-methylcarbamoyl)cysteine

AMCC

if Et

not Me: AECC

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gate, E.N., Threadgill, M.D., Stevens, M.F.G., Chubb, D., Vickers, L.M., Langdon, S.P., Hickman, J.A. & Gescher, A. (1986) J. Med. Chem. 29, 1046–1052.CrossRefGoogle Scholar
  2. 2.
    Lomax, N.R. & Narayanan, V.L. (1981) in Chemical Structures of Interest to the Division of Cancer Treatment, Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program, Nat. Cancer Inst.: Bethesda, MD.Google Scholar
  3. 3.
    Kestell, P., Threadgill, M.D., Gescher, A., Gledhill, A.P., Shaw, A.J. & Farmer, P.B. (1987) J. Pharmacol. Exp. Ther. 240, 265–270.Google Scholar
  4. 4.
    Kestell, P., Gill, M.H., Threadgill, M.D., Gescher, A., Howarth, O.W. & Curzon, E.H. (1986) Life Sci. 38, 719–724.CrossRefGoogle Scholar
  5. 5.
    Brindley, C., Gescher, A. & Ross, D. (1983) Chem.-Biol. Interact. 45, 387–392.CrossRefGoogle Scholar
  6. 6.
    Scailteur, V., Hoffman, E., Buchet, J.P. & Lauwerys, R. (1984) Toxicology 29, 221–234.CrossRefGoogle Scholar
  7. 7.
    Kestell, P., Gledhill, A.P., Threadgill, M.D. & Gescher, A. (1986) Biochem. Pharmacol. 35, 2283–2286.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Michael D. Threadgill
    • 1
  • Andreas Gescher
    • 1
  1. 1.Cancer Research Campaign Experimental Chemotherapy Group Pharmaceutical Sciences InstituteAston UniversityAston Triangle, BirminghamUK

Personalised recommendations